Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87042 Study.

NCT00333788 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00333788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00333788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87042 Study.
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2006
Completion date
April 30, 2010
Enrollment
233 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease